Volume | 0 |
|
|||||
News | - | ||||||
Day High | Low High |
||||||
Day Low |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Arvinas Inc | ARVN | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
41.33 |
Trades | Volume | Avg Volume | 52 Week Range |
---|---|---|---|
0 | 0 | - | 13.57 - 53.08 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
- | 0 | $ 41.33 | USD |
Arvinas (ARVN) Options Flow Summary
Arvinas Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
2.81B | 68.08M | - | 78.5M | -367.3M | -5.39 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Arvinas News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ARVN Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 44.75 | 44.85 | 40.34 | 41.75 | 419,497 | -3.42 | -7.64% |
1 Month | 47.46 | 51.51 | 40.34 | 44.72 | 805,670 | -6.13 | -12.92% |
3 Months | 41.24 | 53.08 | 35.415 | 44.55 | 769,199 | 0.09 | 0.22% |
6 Months | 20.33 | 53.08 | 13.57 | 34.61 | 766,131 | 21.00 | 103.30% |
1 Year | 26.41 | 53.08 | 13.57 | 31.45 | 593,294 | 14.92 | 56.49% |
3 Years | 59.72 | 108.465 | 13.57 | 48.40 | 496,501 | -18.39 | -30.79% |
5 Years | 15.51 | 108.465 | 13.57 | 47.06 | 481,738 | 25.82 | 166.47% |
Arvinas Description
Arvinas Inc is a United States-based private biopharmaceutical company focused on developing first-in-class protein degradation therapeutics for cancers and other difficult-to-treat diseases. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. Its pipeline candidates include metastatic castration-resistant prostate cancer, metastatic ER-breast cancer, additional oncology indications, tauopathies, and other neurodegenerative diseases. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766. |